Phase 3 RCT Shows Perioperative Enfortumab Vedotin and Pembrolizumab Benefit Muscle-Invasive Bladder Cancer
New Hope for Bladder Cancer Patients Who Can’t Tolerate Standard Chemo
This phase 3 randomized controlled trial enrolled 344 patients with muscle-invasive bladder cancer ineligible for cisplatin-based chemothera…
A new two-drug treatment more than doubles the odds of staying cancer-free for bladder cancer patients who can't handle standard chemo.
Systematic review of 2025 RCTs identifies new standards of care across genitourinary cancers
New standards of care established for bladder, kidney, prostate, testicular, and penile cancers in 2025.
A systematic review and meta-analysis of 40 phase II/III RCTs in patients with bladder, kidney, prostate, testicular, and penile cancers fou…
New 2025 standards of care for bladder, kidney, prostate, testicular, and penile cancers now emphasize biomarker-driven strategies and immun…